Skip to main content
. 2017 Feb 27;49(4):1153–1163. doi: 10.4143/crt.2016.463

Fig. 3.

Fig. 3.

The line charts show the individual changes in estradiol (E2) (A) and follicle-stimulating hormone (FSH) (B) between baseline and at progression in patients treated with aromatase inhibitors and gonadotropin-releasing hormone agonist. The value of same individuals on each graphs are marked with same symbols. Only patients with increased E2 levels compared to baseline are marked.